Investment Manager

OrbiMed Capital LLC

OrbiMed is owned by seven principals, including Samuel D. Isaly, who between them have many years experience of valuing companies in the pharmaceutical, biotechnology and healthcare sectors.

OrbiMed’s investment team includes over 40 experienced professionals with expertise in the life sciences industry, finance, and law. Many have advanced degrees in science and medicine. OrbiMed’s distinctive structure combines the focus of analysts dedicated to specific market sub-sectors with the synergies of public equity and private equity professionals collaborating in a seamlessly integrated platform.

OrbiMed’s professionals seek an exceptional level of research intensity within their healthcare universe of over 750 publicly-traded and 2.000 privately-held companies. The team has a demonstrable record of seeking successful investments across market cycles in both public and private companies.

Samuel D. Isaly

Sam is a founder and the Managing Partner of OrbiMed Advisors. He is one of the world’s most recognised healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Sam has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, SoGen Swiss International, Gramercy Associates and S.G. Warburg. Sam launched OrbiMed’s asset management business in 1989. He has a B.A. in Economics from Princeton University and a M. Sc. (Econ.) from The London School of Economics.

For more information on OrbiMed, please see their website: www.orbimed.com